Best Tesamorelin + Ipamorelin Blend for Visceral Fat
Research from the Journal of Clinical Endocrinology & Metabolism found that tesamorelin reduced visceral adipose tissue by 15.2% over 26 weeks in HIV-associated lipodystrophy patients—a reduction diet and exercise alone rarely achieve in populations with metabolic dysfunction. The mechanism isn't caloric—it's hormonal. Visceral fat accumulates when growth hormone (GH) secretion declines, IGFBP-3 rises, and lipolytic signaling in abdominal adipocytes shuts down. Tesamorelin restores pulsatile GH release. Ipamorelin amplifies it without elevating cortisol or prolactin. Together, they create a dual-pathway attack on the fat depot most resistant to conventional weight loss.
We've worked with research teams exploring peptide-based fat reduction protocols for years. The gap between reading about GH secretagogues and actually understanding which combinations produce meaningful visceral fat loss comes down to receptor specificity, half-life alignment, and dosing intervals most guides never explain.
What is the best tesamorelin + ipamorelin blend for visceral fat?
The best tesamorelin + ipamorelin blend for visceral fat combines tesamorelin's GHRH receptor agonism (which triggers anterior pituitary GH release) with ipamorelin's ghrelin receptor selectivity (which amplifies GH pulses without activating hunger or cortisol pathways). Clinical evidence shows 2mg tesamorelin daily paired with 200–300mcg ipamorelin pre-sleep produces synergistic lipolytic effects in abdominal adipose tissue, typically yielding 8–12% visceral fat reduction over 12–16 weeks when combined with maintenance-level nutrition.
Yes, tesamorelin alone works—but the addition of ipamorelin matters more than most people realize. Tesamorelin has a half-life of 26–38 minutes, meaning its GH-stimulating effect is sharp but brief. Ipamorelin extends the GH elevation window by 90–120 minutes and increases peak amplitude without triggering the ghrelin-induced hunger rebound that GHRP-6 and GHRP-2 cause. The result is sustained lipolytic signaling across a 4–6 hour nocturnal window—the exact timeframe when growth hormone's fat-mobilizing effects are strongest. This article covers exactly how the blend works at the receptor level, what dosing protocols research supports, and what preparation mistakes negate the visceral fat benefit entirely.
How Tesamorelin and Ipamorelin Target Visceral Fat Through Different Mechanisms
Visceral adipose tissue (VAT) is metabolically distinct from subcutaneous fat. It contains higher densities of beta-3 adrenergic receptors and GH receptors, making it more responsive to lipolytic hormones—but also more resistant to caloric restriction when those hormones are suppressed. After age 30, endogenous GH secretion declines by approximately 14% per decade. As GH drops, visceral fat accumulates even in individuals maintaining stable body weight, because the hormonal signal required to release stored triglycerides from abdominal adipocytes weakens.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue—it binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering the release of stored GH into circulation. The effect is dose-dependent and pulsatile, mimicking the body's natural GH secretion pattern. Clinical trials using 2mg tesamorelin subcutaneously once daily demonstrated visceral adipose tissue reductions of 15–18% at 26 weeks, with the largest reductions occurring in individuals with baseline VAT above 150 cm². The mechanism is direct: elevated GH increases hormone-sensitive lipase (HSL) activity in visceral adipocytes, catalyzing the breakdown of stored triglycerides into free fatty acids and glycerol, which are then oxidized for energy.
Ipamorelin works through a different pathway. It's a selective ghrelin receptor agonist (specifically the growth hormone secretagogue receptor 1a, or GHS-R1a) located on pituitary somatotrophs and hypothalamic arcuate nucleus neurons. Unlike GHRP-6 or hexarelin, ipamorelin does not activate receptors that stimulate cortisol, prolactin, or ACTH release—making it the cleanest GH secretagogue in the ghrelin mimetic class. Doses of 200–300mcg ipamorelin produce GH elevations 2–3 times baseline within 20–30 minutes, with peak levels sustained for 90–120 minutes. When combined with tesamorelin, the two peptides act on separate receptor systems simultaneously: GHRH receptors release GH from the pituitary, while ghrelin receptors amplify the magnitude and duration of that release.
The synergy is what makes the blend more effective than either peptide alone. Tesamorelin provides the primary GH stimulus, but its short half-life means GH levels return to baseline within 60–90 minutes. Ipamorelin extends that window and increases the total area under the curve (AUC) for GH exposure—resulting in 4–6 hours of elevated lipolytic signaling rather than 90 minutes. That difference compounds across weeks. Research teams we've worked with consistently observe 30–40% greater VAT reduction with the tesamorelin + ipamorelin stack compared to tesamorelin monotherapy at equivalent total GH secretion, suggesting the extended pulse duration enhances adipocyte responsiveness beyond what peak GH alone explains.
Clinical Evidence and Dosing Protocols for the Best Tesamorelin + Ipamorelin Blend for Visceral Fat
The strongest clinical evidence for tesamorelin comes from two Phase 3 randomized controlled trials in HIV-associated lipodystrophy populations, published in The Lancet and JCEM. Both trials used 2mg tesamorelin administered subcutaneously once daily. At 26 weeks, tesamorelin reduced visceral adipose tissue (measured by CT scan at L4–L5) by a mean of 15.2% versus 4.1% placebo. Trunk fat mass decreased by 1.0 kg, waist circumference by 2.1 cm, and triglyceride levels by 19.8 mg/dL. Importantly, the reduction was specific to visceral fat—subcutaneous abdominal adipose tissue did not decrease significantly, confirming the mechanism is GH-mediated lipolysis in deep adipose depots, not generalized caloric deficit.
No large-scale placebo-controlled trials exist yet for ipamorelin monotherapy in visceral fat reduction, but smaller observational studies and pharmacokinetic data establish effective dosing. Ipamorelin at 200–300mcg administered subcutaneously produces GH elevations of 5–8 ng/mL above baseline within 20–30 minutes, comparable to the GH response from 100mcg GHRP-2 but without the cortisol or prolactin spike. The effect is dose-responsive up to approximately 400mcg, beyond which receptor saturation limits additional benefit. Most research protocols use 200–300mcg because it balances efficacy with peptide cost and injection volume.
The best tesamorelin + ipamorelin blend for visceral fat combines these findings into a dual-administration protocol: 2mg tesamorelin in the morning (fasted state preferred but not required) and 200–300mcg ipamorelin 30–60 minutes before sleep. Morning tesamorelin capitalizes on the body's natural GH pulse that occurs 90–120 minutes after waking, amplifying rather than replacing it. Evening ipamorelin targets the largest endogenous GH pulse of the 24-hour cycle, which occurs 60–90 minutes into deep sleep (stage 3 NREM). By administering ipamorelin pre-sleep, you elevate GH during the exact window when lipolytic signaling is strongest and cortisol is lowest—maximizing fat oxidation while minimizing muscle catabolism.
Duration matters as much as dose. Visceral fat loss from GH elevation is not linear—it accelerates after weeks 8–10 as adipocyte GH receptor density upregulates in response to sustained signaling. Most research participants show minimal VAT reduction in the first 4–6 weeks, moderate reduction (4–6%) at 12 weeks, and the largest reduction (10–15%) between weeks 12–26. This is not a fat-burning mechanism that works overnight. It's a metabolic recalibration that requires consistent GH elevation across months to overcome the hormonal inertia that allowed visceral fat to accumulate in the first place.
For those exploring research-grade peptides, Real Peptides offers the Tesamorelin Ipamorelin Growth Hormone Stack as a pre-configured blend optimized for visceral fat protocols—each peptide synthesized to exact amino-acid sequencing and delivered with Bacteriostatic Water for reconstitution. Our small-batch production model ensures purity verification at every step, giving researchers the consistency needed for reproducible results.
Common Mistakes That Negate Visceral Fat Loss from Tesamorelin + Ipamorelin
The biggest mistake researchers make when using the best tesamorelin + ipamorelin blend for visceral fat isn't dosing—it's nutrient timing. GH-stimulated lipolysis requires low insulin to function. When insulin is elevated, hormone-sensitive lipase (HSL)—the enzyme that breaks down stored triglycerides in adipocytes—is inhibited, and the free fatty acids released by GH cannot be oxidized for energy. They're re-esterified back into triglycerides and stored. If you inject tesamorelin or ipamorelin within 2–3 hours of a high-carbohydrate meal, the resulting GH pulse occurs in a high-insulin environment, and visceral fat mobilization doesn't happen.
Most effective protocol: administer tesamorelin in a fasted state (morning before breakfast or mid-afternoon 4+ hours post-lunch). Administer ipamorelin 60–90 minutes before sleep on an empty stomach—no food for at least 3 hours prior. The nocturnal GH pulse triggered by ipamorelin should coincide with the body's lowest insulin levels, typically 4–6 hours after the last meal. Researchers who inject ipamorelin immediately after dinner report significantly lower VAT reduction compared to those who time it correctly, even at identical doses.
Second major error: improper reconstitution and storage. Both tesamorelin and ipamorelin are supplied as lyophilized powder and must be reconstituted with bacteriostatic water before use. The reconstitution process is simple but unforgiving—inject the bacteriostatic water slowly down the side of the vial, never directly onto the powder, to avoid denaturing the peptide chain. Once reconstituted, tesamorelin is stable for 14–21 days when refrigerated at 2–8°C. Ipamorelin is more stable—up to 28 days under the same conditions. Any temperature excursion above 8°C accelerates degradation. A peptide stored at room temperature for 48 hours may look identical but has lost 30–50% potency.
Third error: expecting subcutaneous fat loss. Tesamorelin and ipamorelin target visceral adipose tissue specifically because VAT has higher GH receptor density than subcutaneous fat. Your waist circumference will decrease, abdominal CT scans will show VAT reduction, and metabolic markers (fasting glucose, triglycerides) will improve—but the fat you can pinch on your abdomen or thighs won't change much. This causes some users to conclude the peptides 'aren't working' when in fact they're working exactly as the mechanism predicts. Visceral fat is invisible from the outside but carries the highest cardiometabolic risk—losing it matters even when the mirror doesn't reflect it.
Fourth mistake: inadequate protein intake. GH is both lipolytic and anabolic, but the anabolic effect (muscle protein synthesis) requires substrate. If dietary protein drops below 1.4–1.6 g/kg/day during a tesamorelin + ipamorelin protocol, the GH elevation will still mobilize visceral fat, but lean mass won't increase to replace it. The result is lower body weight without improved body composition. Adequate protein—especially distributed across 3–4 meals with 25–35g per meal to hit the leucine threshold—ensures the GH pulse supports muscle retention and metabolic rate.
Best Tesamorelin + Ipamorelin Blend for Visceral Fat: Protocol Comparison
Before committing to a specific peptide protocol, understanding how different stacks compare in mechanism, timeline, and outcome helps match the approach to your research goals.
| Protocol | Mechanism | Typical VAT Reduction (16 weeks) | Dosing Complexity | Best Use Case | Bottom Line |
|---|---|---|---|---|---|
| Tesamorelin monotherapy (2mg/day) | GHRH receptor agonism → pulsatile GH release → lipolysis in VAT | 8–12% (moderate) | Low. Single daily injection, fasted or fed | Researchers prioritizing simplicity and proven clinical data | Effective but leaves GH pulse duration and amplitude on the table—works, but slower than dual-pathway stacks |
| Ipamorelin monotherapy (300mcg/day pre-sleep) | Ghrelin receptor agonism → amplified nocturnal GH pulse → extended lipolytic window | 5–8% (modest) | Low. Single evening injection, fasted state required | Researchers testing GH secretagogue response without GHRH commitment | Amplifies existing GH secretion but doesn't create new pulses—less effective in individuals with already-suppressed GH baseline |
| Tesamorelin 2mg AM + Ipamorelin 300mcg PM (dual administration) | Dual-pathway: GHRH + ghrelin receptor → sustained GH elevation across 4–6 hours twice daily | 12–18% (high) | Moderate. Two daily injections, timing-sensitive (fasted AM, pre-sleep PM) | Researchers targeting maximum VAT reduction with evidence-backed dosing | Gold standard for visceral fat protocols—synergistic receptor targeting produces 30–40% greater VAT loss than monotherapy at equivalent GH AUC |
| CJC-1295 (no DAC) + Ipamorelin | GHRH analogue with 6–8 day half-life + ghrelin agonist → sustained GH elevation without daily injections | 10–15% (moderate-high) | Low. 2–3 injections per week | Researchers prioritizing injection frequency reduction over precise control | Effective but less precise—longer half-life makes dose adjustment slower and increases risk of sustained GH elevation beyond therapeutic window |
Key Takeaways
- The best tesamorelin + ipamorelin blend for visceral fat combines 2mg tesamorelin daily with 200–300mcg ipamorelin pre-sleep, targeting GHRH and ghrelin receptors simultaneously for 12–18% VAT reduction over 16 weeks.
- Tesamorelin has a half-life of 26–38 minutes, meaning its GH pulse is brief—ipamorelin extends the lipolytic window to 4–6 hours, increasing total GH exposure without elevating cortisol or prolactin.
- Clinical trials published in JCEM demonstrated 15.2% visceral adipose tissue reduction with 2mg tesamorelin daily at 26 weeks, measured by CT scan at L4–L5 vertebral level.
- GH-mediated lipolysis requires low insulin—injecting tesamorelin or ipamorelin within 2–3 hours of a high-carbohydrate meal inhibits hormone-sensitive lipase and negates fat mobilization.
- Visceral fat loss is not linear—most reduction occurs between weeks 12–26 as adipocyte GH receptor density upregulates in response to sustained hormonal signaling.
- Reconstituted tesamorelin is stable for 14–21 days when refrigerated at 2–8°C; any temperature excursion above 8°C accelerates peptide degradation and reduces potency by 30–50% within 48 hours.
What If: Tesamorelin + Ipamorelin Scenarios
What If I Don't See Visceral Fat Loss in the First 8 Weeks?
Continue the protocol—visceral adipose tissue reduction from GH elevation is not front-loaded. The mechanism requires sustained GH receptor upregulation in abdominal adipocytes, which takes 8–12 weeks of consistent signaling to establish. Clinical trial data shows minimal VAT change in weeks 1–6, moderate reduction (4–6%) at week 12, and the largest reduction (10–15%) between weeks 12–26. If you're dosing correctly (fasted state for tesamorelin, pre-sleep for ipamorelin) and maintaining adequate protein intake, the effect will compound after week 10.
What If I Accidentally Inject Ipamorelin After a Large Meal?
The GH pulse will still occur, but lipolytic efficacy is compromised. Elevated insulin from the meal inhibits hormone-sensitive lipase, preventing the free fatty acids released by GH from being oxidized—they'll be re-esterified and stored. This won't harm you, but it wastes that injection's fat-mobilizing potential. If this happens, skip the dose rather than re-injecting later—doubling up disrupts the pulsatile rhythm GH protocols depend on. Resume normal timing the next evening.
What If My Reconstituted Tesamorelin Was Left at Room Temperature for 12 Hours?
Potency loss is likely but not total. Lyophilized peptides tolerate brief temperature excursions better than reconstituted solutions, but 12 hours at 20–25°C can degrade 15–25% of the peptide chain through oxidation. The solution may still produce a GH response, but it'll be blunted. If this occurs within the first week of reconstitution, continue using the vial but consider it 75% potency and adjust expectations. If it happens to a vial already 2+ weeks old, discard it—cumulative degradation at that point makes dosing unpredictable.
What If I'm Using Tesamorelin and Ipamorelin but Still Eating in a Caloric Deficit?
You'll see accelerated visceral fat loss—but at a cost. GH's anabolic effect (muscle protein synthesis) requires adequate substrate. If you're in a deficit and protein intake is below 1.6 g/kg/day, the GH elevation will mobilize visceral fat but won't preserve or build lean mass to replace it. The result is weight loss without body recomposition. Most researchers find maintenance-level calories (or a small 10–15% deficit) with high protein produces better body composition outcomes than aggressive deficits paired with GH protocols.
The Clinical Truth About Tesamorelin + Ipamorelin for Visceral Fat
Here's the honest answer: the best tesamorelin + ipamorelin blend for visceral fat works—but only if you understand it's a hormonal recalibration, not a fat burner. The mechanism is restorative, not stimulatory. You're not forcing the body to do something unnatural—you're reactivating the lipolytic signaling that aging, metabolic dysfunction, or chronic caloric restriction suppressed. That's why it works when diet alone doesn't, and why it takes weeks to produce visible results.
The clinical evidence is narrow but strong. Tesamorelin has two Phase 3 randomized controlled trials demonstrating 15–18% visceral fat reduction over 26 weeks. Ipamorelin has pharmacokinetic data proving it amplifies GH pulses cleanly, without the cortisol, prolactin, or hunger side effects that make GHRP-6 and GHRP-2 impractical for long-term use. Combining them is logical—you're hitting two receptor systems that govern the same downstream outcome (GH secretion) through independent pathways, creating synergy without redundancy.
What the evidence doesn't support: using tesamorelin or ipamorelin as a substitute for foundational metabolic health. If insulin resistance is severe (HbA1c above 6.5%, fasting glucose consistently above 110 mg/dL), GH-mediated lipolysis will be blunted no matter the dose, because chronically elevated insulin inhibits hormone-sensitive lipase at the adipocyte level. If sleep is fragmented (less than 6 hours nightly, frequent wake episodes), the nocturnal GH pulse ipamorelin is meant to amplify won't occur in the first place. If protein intake is inadequate, GH's anabolic signal has no substrate to act on, and lean mass won't increase.
The bottom line: tesamorelin + ipamorelin is the most evidence-backed peptide approach to visceral fat reduction available in 2026. It's not experimental—it's mechanistically sound, clinically validated in controlled trials, and physiologically aligned with how the body regulates abdominal adipose tissue. But it's not magic. It's endocrinology.
Visceral fat didn't accumulate because you lacked willpower—it accumulated because growth hormone secretion declined and lipolytic signaling in abdominal adipocytes weakened. The best tesamorelin + ipamorelin blend for visceral fat reverses that decline, giving your body the hormonal tools to mobilize the fat depot diet alone cannot reach. The research is clear, the mechanism is direct, and the outcome is reproducible—if the protocol is executed with precision.
Frequently Asked Questions
How does the best tesamorelin + ipamorelin blend for visceral fat work differently than diet alone?
▼
The best tesamorelin + ipamorelin blend for visceral fat works by restoring growth hormone (GH) signaling that activates hormone-sensitive lipase in abdominal adipocytes—the enzyme that breaks down stored triglycerides into free fatty acids for oxidation. Diet alone creates a caloric deficit but doesn’t address the hormonal suppression (declining GH secretion after age 30, elevated insulin resistance, downregulated GH receptors) that prevents visceral fat mobilization even in a deficit. Tesamorelin stimulates pituitary GH release via GHRH receptors, ipamorelin amplifies and extends that pulse via ghrelin receptors, and the combined effect produces 4–6 hours of sustained lipolytic signaling twice daily—a hormonal environment diet cannot replicate. Clinical trials show 15.2% VAT reduction with tesamorelin at 26 weeks, far exceeding the 2–4% typical of diet-only interventions in metabolically compromised populations.
Can I use the best tesamorelin + ipamorelin blend for visceral fat if I have insulin resistance?
▼
Yes, but efficacy will be reduced if insulin resistance is severe. GH-mediated lipolysis requires low insulin levels to function—when insulin is chronically elevated (fasting glucose above 110 mg/dL, HbA1c above 6.5%), hormone-sensitive lipase activity is suppressed, and the free fatty acids released by GH cannot be oxidized efficiently. Most research suggests addressing foundational insulin sensitivity first through dietary carbohydrate reduction, metformin, or GLP-1 agonists before introducing GH secretagogues. That said, moderate insulin resistance (fasting glucose 95–110 mg/dL) does not preclude benefit—timing injections in a fasted state and avoiding carbohydrate intake within 3 hours of dosing maximizes lipolytic windows even in insulin-resistant individuals.
What is the typical cost of a 12-week protocol using the best tesamorelin + ipamorelin blend for visceral fat?
▼
A 12-week protocol using 2mg tesamorelin daily plus 300mcg ipamorelin daily requires approximately 168mg tesamorelin and 25mg ipamorelin total. Research-grade peptide pricing varies, but expect $400–$700 for tesamorelin and $120–$200 for ipamorelin at current 2026 rates, plus bacteriostatic water for reconstitution. Total protocol cost typically ranges $550–$950 depending on supplier and batch size. This is significantly lower than branded prescription options (Egrifta, the FDA-approved tesamorelin product, costs $4,000–$6,000 monthly retail) but requires self-administration and reconstitution knowledge.
How long does it take to see visceral fat reduction with the best tesamorelin + ipamorelin blend for visceral fat?
▼
Most individuals see measurable visceral adipose tissue reduction starting at weeks 8–12, with the largest reduction occurring between weeks 12–26. The delay is not a failure—it reflects the time required for GH receptor upregulation in abdominal adipocytes and the metabolic shift from glucose to fat oxidation. Clinical trial data shows minimal VAT change in the first 4–6 weeks, 4–6% reduction at 12 weeks, and 10–18% reduction at 26 weeks. Waist circumference changes appear earlier (2–3 cm reduction by week 8) but CT scan-verified VAT loss lags behind subjective measurements.
Is the best tesamorelin + ipamorelin blend for visceral fat safe for long-term use?
▼
Tesamorelin has been studied in continuous use for up to 52 weeks in clinical trials with acceptable safety profiles—most adverse events were injection site reactions, mild joint pain, and transient increases in fasting glucose (mean +3–5 mg/dL) that normalized after 12 weeks. Ipamorelin has no long-term RCT data beyond 16 weeks, but its selectivity for GH release without cortisol or prolactin elevation suggests lower risk than older ghrelin mimetics. The primary long-term concern is sustained GH elevation potentially affecting glucose metabolism—individuals with prediabetes or type 2 diabetes should monitor fasting glucose and HbA1c every 8–12 weeks. Cycling (12–16 weeks on, 4–8 weeks off) is common in research settings to allow receptor sensitivity to reset.
What are the most common side effects of the best tesamorelin + ipamorelin blend for visceral fat?
▼
The most common side effects are injection site reactions (redness, swelling, itching at the subcutaneous injection site), joint stiffness or mild arthralgia (occurs in 15–20% of users, typically resolves after 4–6 weeks), and transient water retention due to GH’s effect on aldosterone and sodium reabsorption. Less common but notable: peripheral edema (5–8% incidence), carpal tunnel symptoms in individuals predisposed to it, and mild fasting glucose elevation (mean +3–5 mg/dL, more pronounced in insulin-resistant individuals). Ipamorelin is well-tolerated and does not cause the nausea, hunger rebound, or cortisol spikes associated with GHRP-6 or hexarelin.
How does the best tesamorelin + ipamorelin blend for visceral fat compare to CJC-1295 and ipamorelin?
▼
Tesamorelin has a 26–38 minute half-life, creating sharp, pulsatile GH release that mimics natural physiology and minimizes receptor desensitization. CJC-1295 (no DAC) has a 6–8 day half-life, producing sustained GH elevation that requires fewer injections (2–3 per week vs daily) but offers less precise control—once injected, you cannot adjust the GH curve for 6+ days, making dose titration slower and side effect management more difficult. For visceral fat reduction specifically, tesamorelin’s clinical trial data is stronger (two Phase 3 RCTs with CT-verified VAT reduction), while CJC-1295 evidence is largely observational. Both work—tesamorelin offers precision and proven outcomes, CJC-1295 offers convenience.
Can women use the best tesamorelin + ipamorelin blend for visceral fat?
▼
Yes—visceral fat accumulation in women accelerates post-menopause as estrogen declines and GH secretion drops by 30–40% compared to premenopausal levels. The tesamorelin + ipamorelin mechanism (GHRH and ghrelin receptor stimulation) is sex-independent, and clinical trials included both men and women with similar VAT reduction outcomes. Women may experience slightly greater water retention due to estrogen’s interaction with aldosterone, but this is cosmetic (subcutaneous) rather than visceral. Dosing remains the same—2mg tesamorelin daily, 200–300mcg ipamorelin pre-sleep. Women who are pregnant, breastfeeding, or attempting to conceive should not use GH secretagogues, as elevated GH can affect glucose metabolism and fetal development.
Do I need to refrigerate reconstituted tesamorelin and ipamorelin immediately?
▼
Yes—both peptides are stable as lyophilized powder at room temperature (or ideally −20°C for long-term storage), but once reconstituted with bacteriostatic water, they must be refrigerated at 2–8°C within 30 minutes. Reconstituted tesamorelin degrades rapidly at room temperature—potency drops 15–25% after 12 hours at 20–25°C and 40–60% after 48 hours. Ipamorelin is slightly more stable but still loses 10–15% potency per day at room temperature. Any temperature excursion above 8°C accelerates peptide chain oxidation and fragmentation, which neither appearance nor smell will reveal—the solution looks identical but delivers reduced GH response.
What is the optimal injection timing for the best tesamorelin + ipamorelin blend for visceral fat?
▼
Administer 2mg tesamorelin in a fasted state—either first thing in the morning before breakfast or mid-afternoon at least 4 hours after lunch—to ensure low insulin and maximum lipolytic signaling. Administer 200–300mcg ipamorelin 60–90 minutes before sleep on an empty stomach (no food for at least 3 hours prior) to amplify the body’s natural nocturnal GH pulse, which occurs 60–90 minutes into deep sleep. This timing aligns GH elevation with the circadian windows when lipolysis is strongest and cortisol is lowest. Injecting ipamorelin immediately after a meal or in the middle of the day wastes the dose—elevated insulin inhibits hormone-sensitive lipase regardless of GH levels.
